Edited by
Wayne Alves, Valeant Pharmaceuticals Inc., Costa Mesa, CA, USA
Brett Skolnick, Novo Nordisk Pharmaceuticals, Inc., Princeton, NJ, USA
Description
During the 1990’s, scientific advances in understanding the mechanisms and pathophysiology of acute central nervous system injury were
offset by a history of disappointing results from Phase III clinical trials of novel neuroprotective drugs. Numerous novel compounds
were “tested,” and seemingly fell by the wayside. This book is intended to focus on novel therapies and the unique challenges their intended
targets pose for the design and analysis of clinical trials. The authors explore the issues facing research in this area and the strategies
that might lead to future success in this critical area of unmet medical need. It represents a compendium of information gained from
over 20 years of clinical trial experience in areas of acute neurology and neurosurgery. From the knowledge of clinical assessment using
standardized tools, to the intricate design of difficult hyper-acute neuroemergencies trials, the reader will benefit from the authors’
perspectives.
Audience:
Researchers involved with the design of neuroemergency clinical trials, at research labs in universities, hospitals, major pharmaceutical
(e.g., Astra Zeneca, GSK), biotechnology companies involved in these clinical areas.
